Ontology highlight
ABSTRACT: Background/aims
Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).Methods
A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS.Results
The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (?400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008).Conclusions
MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.
SUBMITTER: Yang H
PROVIDER: S-EPMC5497665 | biostudies-literature | 2017 Jun
REPOSITORIES: biostudies-literature
Yang Hyun H Woo Hyun Young HY Lee Soon Kyu SK Han Ji Won JW Jang Bohyun B Nam Hee Chul HC Lee Hae Lim HL Lee Sung Won SW Song Do Seon DS Song Myeong Jun MJ Oh Jung Suk JS Chun Ho Jong HJ Jang Jeong Won JW Lozada Angelo A Bae Si Hyun SH Choi Jong Young JY Yoon Seung Kew SK
Clinical and molecular hepatology 20170510 2
<h4>Background/aims</h4>Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).<h4>Methods</h4>A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients w ...[more]